One of the main findings of this study was that poziotinib concentration-dependently increased the efficacy of mitoxantrone and SN-38 in ABCG2-overexpressing S1-M1-80 colon cancer cells and ABCG2 transfected HEK293/ABCG2 cells. Here, ABCG2 is linked to malignant colon neoplasm.